Faron Pharmaceuticals has raised its cash reserves to €32 million, extending its financial runway to November 2027, enabling continued progress on its BEXERA trial for high-risk myelodysplastic syndrome. The phase IIb trial will start in late 2026, testing bexmarilimab with azacitidine against placebo, aiming for a complete response. Recent mature data showed promising results, including an 85% overall response rate and increased median duration of complete response to 16.1 months. This funding and data position Faron well for upcoming trial milestones and potential value growth.
Olivia Nottebohm, Chief Operating Officer of Box, sold 5,834 shares of the company, generating $188,500 from the transaction. This insider sale could indicate personal financial planning or a shift in confidence, but without further context, its impa...
J.M. Smucker reported a strong first quarter with adjusted earnings of $3.24 per share, a 71% increase year-over-year, and revenue of $2.2 billion, beating analyst expectations. The company showed robust financial health with free cash flow of $337.3...
Vision Marine Technologies' stock jumped 32% following a 1-for-10 reverse stock split and voluntary delisting from the TSX Venture Exchange to focus on Nasdaq. The reverse split reduced shares from 6.53 million to 653,000, boosting the share price bu...
Electromed reported record fiscal Q4 earnings of $0.39 per share, beating estimates by nearly 22%, with revenue up 11.6% to $19.42 million, though slightly missing revenue expectations. Despite this, shares fell over 18% following the announcement of...
Veeva Systems, a leading cloud software provider for life sciences, is expected to report strong Q3 earnings on August 26, 2026, with analysts projecting revenue of about $905 million and EPS of $2.22, an 11.6% increase year-over-year. The company be...
